Phio Pharmaceuticals Corp. financial data

Symbol
PHIO on Nasdaq
Location
11 Apex Drive, Suite 300 A, Pmb 2006, Marlborough, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 824 % +80.1%
Debt-to-equity 14 %
Return On Equity -86.4 % +35.8%
Return On Assets -75.8 % +30.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.8M shares +920%
Common Stock, Shares, Outstanding 5.78M shares +504%
Entity Public Float 3.2M USD -43.9%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 5.47M shares +452%
Weighted Average Number of Shares Outstanding, Diluted 4.79M shares +840%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.13M USD +12.6%
General and Administrative Expense 4.23M USD +10.8%
Operating Income (Loss) -8.36M USD -9.83%
Nonoperating Income (Expense) 143K USD +110%
Net Income (Loss) Attributable to Parent -7.95M USD -7.2%
Earnings Per Share, Basic -4 USD/shares +81.5%
Earnings Per Share, Diluted -5 USD/shares +83%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.7M USD +98.6%
Assets, Current 11.5M USD +96%
Property, Plant and Equipment, Net 12K USD +1100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 11.5M USD +96.2%
Accounts Payable, Current 516K USD +180%
Employee-related Liabilities, Current 31K USD -86%
Accrued Liabilities, Current 1.15M USD +56.5%
Liabilities, Current 1.21M USD -20.8%
Operating Lease, Liability, Noncurrent 0 USD
Liabilities 1.67M USD
Retained Earnings (Accumulated Deficit) -153M USD -5.5%
Stockholders' Equity Attributable to Parent 9.84M USD +98.9%
Liabilities and Equity 11.5M USD +96.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.28M USD +36.6%
Net Cash Provided by (Used in) Financing Activities 9.17M USD
Net Cash Provided by (Used in) Investing Activities -2K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 5.78M shares +504%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.8M USD +129%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 337K USD -86.8%
Deferred Tax Assets, Gross 350K USD -86.3%
Operating Lease, Liability 0 USD -100%
Payments to Acquire Property, Plant, and Equipment 2K USD
Lessee, Operating Lease, Liability, to be Paid 35K USD -80%
Property, Plant and Equipment, Gross 308K USD -73%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year One 35K USD -75%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -106%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 26K USD -96.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares -90%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 0 USD -100%
Additional Paid in Capital 163M USD +8.58%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 0 USD -100%
Share-based Payment Arrangement, Expense 113K USD +117%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%